Caris introduces Caris Assure liquid biopsy assay
July 2022—Caris Life Sciences introduced its Caris Assure liquid biopsy assay at the American Society of Clinical Oncology annual meeting in June.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
Verichem reference materials for ethanol, total protein, albumin
July 2022—Verichem Laboratories announced the availability of clinical reference materials intended for the calibration or calibration verification of ethanol assays.
BioMérieux Chikungunya dx tests get CE mark
July 2022—BioMérieux announced the CE marking of its Vidas Anti-Chikungunya IgM and Anti-Chikungunya IgG tests to diagnose Chikungunya virus infection. The tests can detect infection during the acute phase and into the chronic phase and run on the company’s Vidas immunoassay instruments.
Steripath use studied hospitalwide
July 2022—Magnolia Medical Technologies, developers of the FDA 510(k)-cleared Steripath platform for reducing blood culture contamination for sepsis testing accuracy, announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System.
Creative Dx releases Nipah virus mAb pairs
July 2022—Creative Diagnostics has released a range of Nipah virus recombinant antigens and monoclonal antibody pairs. The monoclonal antibodies can be used as a pair in sandwich ELISA with the recombinant protein or in capture IgM assays. The products are specific to Nipah virus, with no cross-reaction with dengue, Zika, and chikungunya envelope proteins.
GenScript, Euroimmun enter distribution agreement
July 2022—GenScript USA has reached an agreement with Euroimmun US, a PerkinElmer company, for the distribution of the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit in the United States and Canada.
FDA clears Scopio Labs hematology digital cell morphology platform
July 2022—Scopio Labs received FDA 510(k) clearance for its X100HT hematology digital cell morphology platform with peripheral blood smear review.
BD launches infectious disease molecular Dx platform
July 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX. The 510(k)-cleared instrument is an analytic option for the modular and scalable BD COR system.
Streck introduces viral extraction kit
July 2022—Streck, in partnership with Ceres Nanosciences, announced the availability of its viral extraction kit for clinical samples containing SARS-CoV-2 and influenza A.
Illumina introduces pan-cancer CDx
July 2022—Illumina announced that a companion diagnostic indication has been added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions including NTRK1, NTRK2, or NTRK3 and who may benefit from targeted therapy with Bayer’s Vitrakvi (larotrectinib), a genomically matched treatment.